Pharmaceutical - USA, Diabetes

Filter

Current filters:

USADiabetes

Popular Filters

Glowing prospects for Novo Nordisk's insulin degludec/liraglutide for type 2 diabetes

Glowing prospects for Novo Nordisk's insulin degludec/liraglutide for type 2 diabetes

07-07-2014

Danish diabetes care giant Novo Nordisk's fixed-dose combination therapy insulin degludec/liraglutide…

DiabetesEuropeIDegLiraMarkets & MarketingNovo NordiskPharmaceuticalUSAXultophy

FDA approves MannKind’s Afrezza to treat diabetes

FDA approves MannKind’s Afrezza to treat diabetes

30-06-2014

In a much awaited decision, the US Food and Drug Administration on Friday approved MannKind Corp’s…

AfrezzaDiabetesMannKindPharmaceuticalRegulationUSA

FDA review of CV risks for diabetics taking olmesartan not conclusive

FDA review of CV risks for diabetics taking olmesartan not conclusive

25-06-2014

The US Food and Drug Administration has completed its safety review and has found no clear evidence of…

BenicarCardio-vascularDaiichi SankyoDiabetesolmesartanPharmaceuticalRegulationUSA

Novo Nordisk launch new insulin device Levemir FlexTouch in USA

Novo Nordisk launch new insulin device Levemir FlexTouch in USA

19-06-2014

Danish diabetes care giant Novo Nordisk has launched its newest prefilled insulin delivery device Levemir…

DiabetesLevemirMarkets & MarketingNovo NordiskPharmaceuticalUSA

Boehringer and Lilly re-file empagliflozin NDA with FDA

Boehringer and Lilly re-file empagliflozin NDA with FDA

19-06-2014

The US subsidiary of German family-owned drugmaker Boehringer Ingelheim and pharma major Eli Lilly have…

Boehringer IngelheimDiabetesEli LillyempagliflozinPharmaceuticalRegulationUSA

Large increase seen in insulin use, out-of-pocket costs for type 2 diabetes

11-06-2014

Largely attributable to the widespread adoption of insulin analogs, use of insulin among patients with…

DiabetesHealthcarePharmaceuticalPricingUSA

Jury finds in favor of Takeda in diabetes drug Actos case

23-05-2014

The US subsidiary of Japan’s largest drugmaker, Takeda Pharmaceuticals, yesterday announced that in…

ActosDiabetesLegalPharmaceuticalTakeda PharmaceuticalsUSA

FDA finally OKs GlaxoSmithKline’s Tanzeum to treat type 2 diabetes

FDA finally OKs GlaxoSmithKline’s Tanzeum to treat type 2 diabetes

16-04-2014

UK pharma giant GlaxoSmithKline yesterday received the much anticipated approval from the US Food and…

albiglutideDiabetesGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationTanzeumUSA

NDA filing for empagliflozin and linagliptin combo accepted by FDA

NDA filing for empagliflozin and linagliptin combo accepted by FDA

14-04-2014

The US Food and Drug Administration has accepted the filing of the New Drug Application for the investigational…

Boehringer IngelheimDiabetesEli LillyempagliflozinJardiancelinagliptinNorth AmericaPharmaceuticalRegulationTradjentaUSA

Takeda ordered to pay $6 billion damages in Actos trial

Takeda ordered to pay $6 billion damages in Actos trial

08-04-2014

Japan’s largest drugmaker Takeda Pharmaceutical has been ordered to pay $6 billion in punitive damages…

ActosDiabetesEli Lilly and CompanyJapanJudgeLegalMajorPharmaceuticalPyridinesTakeda NycomedThiazolidinedionesUSA

MannKind’s diabetes drug Afrezza recommended by FDA advisory

02-04-2014

The US Food and Drug Administration’s Endocrinologic and Metabolic Drugs Advisory Committee yesterday…

AfrezzaDiabetesMannKindNorth AmericaPharmaceuticalRegulationUSA

FDA issues CRL on empagliflozin, noting manufacturing deficiencies

FDA issues CRL on empagliflozin, noting manufacturing deficiencies

05-03-2014

There was disappointment today for US drug major Eli Lilly and family-owned German pharma firm Boehringer…

Boehringer IngelheimDiabetesEli LillyempagliflozinNorth AmericaPharmaceuticalProductionRegulationUSA

FDA approves Bydureon Pen for type 2 diabetes

FDA approves Bydureon Pen for type 2 diabetes

03-03-2014

Anglo-Swedish drug major AstraZeneca says the US Food and Drug Administration has approved the Bydureon…

AlkermesAmylinAstraZenecaBristol-Myers SquibbBydureonDiabetesPharmaceuticalRegulationUSA

FDA to review heart failure risk with AstraZeneca diabetes drug

FDA to review heart failure risk with AstraZeneca diabetes drug

12-02-2014

The US Food and Drug Administration has requested clinical trial data from Anglo-Swedish drug major AstraZeneca,…

AstraZenecaDiabetesKombiglyzeNorth AmericaOnglyzaPharmaceuticalRegulationResearchUSA

Sanofi sues Eli Lilly over Lantus patent infringement

Sanofi sues Eli Lilly over Lantus patent infringement

31-01-2014

French drug major Sanofi says it has filed a patent infringement suit against USA pharma firm Eli Lilly…

BiosimilarsDiabetesEli LillyLantusLegalNorth AmericaPatentsPharmaceuticalSanofiUSA

US FDA approves AstraZeneca’s Farxiga to treat type 2 diabetes

US FDA approves AstraZeneca’s Farxiga to treat type 2 diabetes

09-01-2014

Reversing a previous 2012 negative decision, the US Food and Drug Administration yesterday approved Anglo-Swedish…

AstraZenecaBristol-Myers SquibbdapagliflozinDiabetesFarxigaNorth AmericaPharmaceuticalRegulationUSA

Genesis 2013: Secrets of B-MS and AstraZeneca Amylin deal revealed

Genesis 2013: Secrets of B-MS and AstraZeneca Amylin deal revealed

16-12-2013

Secrets of how Bristol-Myers Squibb and AstraZeneca arranged a behind-the-scenes deal to buy Amylin were…

AmylinAstraZenecaBristol-Myers SquibbDiabetesInterviewsLegalMergers & AcquisitionsPharmaceuticalUKUSA

Trajenta studies prove efficacy in broad range of diabetes patients

Trajenta studies prove efficacy in broad range of diabetes patients

07-11-2013

Boehringer Ingelheim and Eli Lilly (NYSE: LLY) have released new data that reinforces the efficacy and…

Asia-PacificBoehringer IngelheimDiabetesEli LillyNorth AmericaPharmaceuticalResearchTrajentaUSA

Back to top